Venous clot risk may be higher for adults born prematurely | Scientists develop chikungunya vaccine | Antibiotic lock lowers infection risk in hemodialysis patients
Web Version
 
 
July 29, 2014
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top Story
Venous clot risk may be higher for adults born prematurely
An analysis of data on 3.5 million babies born in Sweden found that premature birth was associated with a greater likelihood of venous blood clots in infancy, early childhood and young adulthood. Girls had a higher chance of clotting as teens and into adulthood. The findings appear in the journal Pediatrics. HealthDay News (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
Science & Health
Scientists develop chikungunya vaccine
Researchers at North Carolina State University have developed a vaccine for chikungunya, and they say the approach they used holds promise for other infectious diseases. "The technology we've developed can now be very rapidly applied to any of the 700 known arthropod-centric viruses," said researcher Dennis Brown. Human trials are planned. The News & Observer (Raleigh, N.C.) (7/25)
Share: LinkedInTwitterFacebookGoogle+Email
Antibiotic lock lowers infection risk in hemodialysis patients
The use of a lock solution of gentamicin and citrate on hemodialysis patients reduced catheter-related bloodstream infections by 73% and death by 68% compared with heparin, according to a study in the Clinical Journal of the American Society of Nephrology. The study evaluated 555 chronic hemodialysis patients from three outpatient centers in Detroit. Gentamicin resistance also declined twofold from control to the antibiotic-lock period, believed to be caused by the use of low doses as opposed to heparin. Renal and Urology News (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
The Technical Manual 18th edition—NOW AVAILABLE
Revised and more relevant than ever, the 18th edition of the Technical Manual includes updated and expanded PBM content, enhanced cellular therapy chapters and inclusion of information on immunohematology reflecting both serologic and molecular aspects. For the first time, methods in SOP format are placed on a USB flash card making them customizable for easy adoption by your facility. Order your copy today!
Advertisement
 
Emerging Trends
New device uses microscopic laser beams to draw blood
Scientists at NoNeedles Venipuncture are developing a new process that uses laser pulses instead of a needle to draw blood. The NoNeedles process involves firing a laser beam through the skin to create a tiny channel into the vein, which is connected to a port to collect the blood. Another laser beam is fired to seal the entry and halt the bleeding. Laser Focus World online (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
Study: 1 in 3,000 blood donors in England may have hepatitis E
About 1 in 3,000 donors in England could be infected with the hepatitis E virus, according to a study in The Lancet that retroactively screened 225,000 blood donations in southeast England. The overall risk of hepatitis E is slight, said lead researcher Dr. Richard Tedder of the Blood Borne Virus Unit at Public Health England. But the virus can cause chronic liver disease in immunocompromised patients, and "a policy is needed to identify these persistently infected patients and provide them with appropriate antiviral treatment," Tedder said. Nursing Times (U.K.) (free registration)/The Press Association (U.K.) (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
Core Principles in Cellular Therapy Now Available
This key resource is derived for a distinct readership in laboratories from the AABB Technical Manual, 18th edition. Methods covered include collection and processing of hematopoietic stem cells (HSCT), umbilical cord blood, blood, marrow and tissue-derive non HSCT sources for use in cell-based therapies. Available now in the AABB Marketplace.
Advertisement
 
Industry News & Practice
Harvard startup to commercialize organs-on-chips
Emulate, a spinoff from Harvard's Wyss Institute for Biologically Inspired Engineering, will work to develop and market organs-on-chips to expedite the development of new drugs. Wyss Institute scientists also have developed a way to allow simulated blood to flow through multiple organ-like devices to simulate the human body. Genetic Engineering & Biotechnology News (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
AstraZeneca signs companion diagnostic deals with Roche, Qiagen
AstraZeneca has tapped Roche Holding and Qiagen to develop separate blood-based tests that can be used as companion diagnostics for its lung cancer treatments. Qiagen's test will be used to identify patients who will benefit from AstraZeneca's established lung cancer drug Iressa, while Roche's assay will serve as a companion diagnostic for the experimental lung cancer treatment AZD9291. Reuters (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
FDA approves expanded label changes for ruxolitinib
The FDA has approved additional labeling for Incyte's myelofibrosis drug ruxolitinib, or Jakafi, that includes new data on survival and information on safety and dosing. The new label also addresses the risk and management of tuberculosis and updates the guidelines for using Jakafi with CYP3A4 inhibitors and fluconazole. eMPR.com (7/28)
Share: LinkedInTwitterFacebookGoogle+Email
FDA accepts Sandoz's biosimilar version of Neupogen for review
The FDA has agreed to review Sandoz's biologics license application for Zarzio, its biosimilar version of Amgen's Neupogen, or filgrastim, which is indicated for reducing infections in patients at risk of neutropenia due to chemotherapy. The application makes the Novartis subsidiary the first company to submit a biologic drug for FDA review under the biosimilars pathway. Sandoz already markets Zarzio in over 40 countries outside the U.S. Reuters (7/24), Chain Drug Review (7/24)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
Motivational speaker, entrepreneur and best-selling author Pat Croce will deliver keynote at AABB's Annual Meeting opening session
AABB has selected Pat Croce to be the keynote speaker at the Annual Meeting opening session, to be held Oct. 25 in Philadelphia. Croce, who began his career as a physical therapist and rose to prominence as a New York Times best-selling author, motivational speaker, restaurant owner and museum founder, will present the success strategies that propelled him from the training room to the boardroom. The former owner of the Philadelphia 76ers, Croce is known as the architect of one of the most amazing turnarounds in NBA history for leading the team from last place to the 2001 championship playoffs during the five years he served as team president.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Collections TrainerBlood Bank of HawaiiHonolulu, HI
APHERESIS MANAGERBlood Bank of HawaiiHonolulu, HI
PROJECT MANAGERBlood Bank of HawaiiHonolulu, HI
Transfusion Services Supervisor (Evenings)Puget Sound Blood CenterSeattle, WA
Clinical Nurse SpecialistPuget Sound Blood CenterSeattle, WA
Click here to view more job listings.
 
SmartQuote
We must open the doors of opportunity. But we must also equip our people to walk through those doors."
-- Lyndon B. Johnson,
36th U.S. president
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information